

Table 2. Summary of profiles of advanced colorectal cancer patients enrolled in the present study and clinical and immunological responses to vaccination with survivin-2B80-88 peptide, IFA and IFN α

| Patient no. | Age/sex | Adverse effects | Tumor markers pre-/post- (CEA ng/mL) | CT evaluation† | Survivin-2B80-88 peptide | | |
|-------------|---------|-----------------|---|----------------|--------------------------|------------|----------|
| | | | | | Tetramer staining‡ | | ELISPOT§ |
| | | | | | Pre-/post- | % increase | |
| 1 | 5/M | Leukopenia | Not determined | SD | 53/98 | 184.9 | - |
| 2 | 62/M | No | 5/3 | SD | 17/33 | 194.1 | - |
| 3 | 65/F | Fever | 561/441 | SD | 11/98 | 890.9 | + |
| 4 | 72/M | No | 6/8 | PD | 69/81 | 117.4 | + |
| 5 | 33/F | Fever | 4655/8651 | PD | 8/24 | 300.0 | + |
| 6 | 44/F | Edema, Fever | 12/2 | SD | 5/76 | 1520.0 | + |
| 7 | 53/F | Fever | 82/117 | PD | 4/555 | 13 875.0 | + |
| 8 | 76/M | No | 63/140 | PD | 32/35 | 109.4 | - |

†Evaluation of CT images was done by the following: PD, progressive disease; SD, stable disease. ‡CTL frequencies of pre- and post-vaccinated patients were assessed with a HLA-A24-restricted survivin-2B80-88 (AYACNTSTL) peptide tetramer, compared with a HLA-A24-restricted HIV peptide (RYLRDQQLL) tetramer used as a negative tetramer control. The number of survivin-2B80-88 peptide tetramer-positive but HIV peptide-negative CTL among 104 CD8 T cells is shown. §Positive (+) ELISPOT represents a more than twofold increase of survivin-2B80-88 peptide-specific CD8 T cell IFN γ -positive spots compared with HIV peptide-specific CD8 T cell spots, whereas negative (-) means a less than twofold increase. CEA, carcinoembryonic antigen; CT, computed tomography; CTL, cytotoxic T lymphocyte; ELISPOT, enzyme-linked immunosorbent spot; HIV, human immunodeficiency virus; IFA, incomplete Freund's adjuvant; IFN, interferon.

Consequently, it appeared that there was a close correlation between clinical SD outcomes and a reduced CEA level.

Immune responses, single-cell cloning and subsequent functional assessment of tetramer-positive CTL. We determined if the survivin-2B80-88 peptide vaccination could actually induce specific immune responses in the patients enrolled. The peptide-specific CTL frequency was analyzed using the HLA-A24/peptide tetramer. The CTL frequency before the first vaccination (pre-vaccination) and after the last vaccination (post-vaccination) was assessed with a HLA-A24-restricted survivin-2B80-88 (AYACNTSTL) peptide tetramer, compared with a HLA-A24-restricted HIV peptide (RYLRDQQLL) tetramer for the negative tetramer control. The number of survivin-2B80-88 peptide tetramer-positive but HIV peptide-negative CD8 T cells in 10⁴ CD8 T cells was determined. In the current study, ELISPOT was also carried out using these peptides.

The data are summarized in Tables 1 and 2. In the first vaccination protocol, that is, vaccination with survivin-2B80-88 plus IFA, patients did not show obvious survivin-2B80-88-specific CTL responses in the tetramer study. Only patients Nos 2 and 3 exhibited very slight enhancement in that study. Patient No. 5 was positive in the ELISPOT study, but did not show a survivin-2B80-88-specific CTL response in the tetramer study. In these patients, there was no correlation between the clinical and immune responses. However, in the second protocol with survivin-2B80-88 plus IFA and IFN α , many patients demonstrated enhanced tetramer frequency. In particular, four of the eight patients (Nos 3, 5, 6 and 7) had enhanced frequency with a more than 200% increase. It was also interesting that all four of these patients were also positive in the ELISPOT study, and two had SD by CT evaluation, suggesting that immune responses might appropriately reflect, at least in some patients, clinical responses with this second vaccination protocol.

Subsequently, we analyzed tetramer-positive CD8 T cells at the single-cell level, and determined whether these T cells had specificity for the survivin-2B80-88 peptide and cytotoxic potential against live survivin-2B-positive tumor cells in the context of HLA-A*2402. As shown in Figure 2, patient No. 6 (44 years old, female) had positive HLA class I expression in rectal tumor tissue (Fig. 2A), a reduced serum CEA level (Fig. 2B) and obvious immune responses as assessed by the survivin-2B80-88 tetramer and ELISPOT (Fig. 2C) after vaccination with the second protocol. CD8 T cells of the tetramer-positive fraction were sorted by FACS, and then cultured with 1,

3 and 10 cells/well for 7–10 days. As shown in Figure 3, almost all growing T cells were survivin-2B peptide-specific T cells, and we subsequently assessed peptide-specific cytotoxicity by using T cells of well (a) through well (h) as indicated. Consequently, as Figure 4 clearly shows, all T cells except for those in well (b) had very high peptide-specific cytotoxic potential. Furthermore, T cells in well (d) were cloned, and we obtained a T cell clone designated D-13 showing survivin-2B peptide specificity as shown in Figure 5A,B. Finally, the cytotoxic potential against survivin-2B-positive live tumor cells was assessed, confirming that the D-13 T cell clone was clearly cytotoxic against survivin-2B-positive tumor cells in a HLA-A*2402-restricted fashion. Taken together, these data clearly indicate that the second vaccination protocol was capable of inducing a strong CTL response, and in some patients might result in clinical effectiveness.

Discussion

The immunogenicity of HLA class I-restricted tumor peptides is not strong enough for routine clinical use as cancer treatment, and it is important to increase their relative and absolute immunogenicity levels by various means. Previously, our group conducted clinical trials of the survivin-2B80-88 peptide vaccine alone and with IFA in patients with various cancers.^(3,8,9,11) In the current study we determined whether the immunogenicity of survivin-2B80-88 could be enhanced with other vaccination protocols. Thus, we compared clinical trials in advanced colon cancer patients with two vaccination protocols: (i) survivin-2B80-88 plus IFA; and (ii) survivin-2B80-88 plus IFA and a type-I IFN, IFN α . Our data strongly suggest that although the effect with survivin-2B80-88 plus IFA was not different from that with the survivin-2B80-88 peptide alone, treatment with survivin-2B80-88 plus IFA and IFN α resulted in clear improvement of the clinical and immunological responses of patients.

There has been less evidence concerning the extent to which peptide-specific CTL responses in patients treated with peptide vaccines could occur at the single-cell level. To assess this point, CTL of patients were sorted to the single-cell level, and we confirmed that each CTL obtained from vaccinated patients was indeed not only peptide-specific but also cytotoxic against human cancer cells in the context of the expression of both HLA-A24 and survivin molecules.




Fig. 2. Representative illustration of clinical effect and immunological analysis in patient No. 6 who was treated with survivin-2B80-88 plus IFA with IFN α . (A) Immunohistochemical analysis of HLA class I expression in primary colon cancer tissue as assessed by anti-HLA class I heavy chain monoclonal antibody EMR8-5, (B) profile of serum CEA level after vaccinations (arrows) and (C) tetramer and ELISPOT analyses before and after vaccinations. The number in the tetramer analysis indicates survivin-2B80-88 peptide-specific CD8 $^+$ T cells among 10 4 CD8 $^+$ T cells. CEA, carcinoembryonic antigen; ELISPOT, enzyme-linked immunosorbent spot; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; IFA, incomplete Freund's adjuvant; IFN, interferon.




Fig. 3. Single-cell analysis of survivin-2B80-88 peptide tetramer-positive CD8 T cells. Survivin-2B80-88 peptide tetramer-positive CD8 T cells in Figure 2C (circle) were sorted and cultured at 10 (A), 3 (B) and 1 (C) cells/well for 7–10 days. Subsequently, cells were examined for their reactivity to the survivin-2B80-88 peptide tetramer.

It is well known that type-I interferons such as IFN α can work in many immunological manners to activate T cell responses.^(22–25) The maturation of dendritic cells (DC) and their effect on the expression of HLA molecules seems to be the main action of this cytokine. Because of difficulties with the availability of patients' samples, we could not actually compare these features of patients' DC and primary tumor tissues before and after treatment with IFN α . However, the evidence of obvious enhancement of CTL responses and improvement of clinical responses in our study favors the two main actions described above. Indeed, a preliminary study of three colon patients who received survivin-2B80-88 plus IFA with GM-CSF did not demonstrate any clinical or immunological response, suggesting that the action of IFN α is remarkable from the aspect of being an immunogenic enhancer for human peptide vaccines. Ideally, patients should be administered IFN α alone before vaccination treatment is undertaken. However, this was practically hard to do since all patients were in the

late and advanced disease stages and it was difficult to select such patients. Meanwhile, there is no evidence that administration of IFN α alone results in overt clinical benefits such as those observed in the current study. The second vaccination protocol using IFN α appeared to be highly efficient for enhancing peptide immunogenicity.

Nevertheless, we require more efficient and reasonable ways to enhance peptide immunogenicity *in vivo* with limited side-effects.⁽²⁶⁾ In our laboratory, it was observed that heat shock protein 90 (HSP90) could highly selectively target substrates such as HLA-class I restricted peptides as well as the innate immunity ligand, CpG, to the Rab5 (+) and EEA1 (+) early static endosomes of DC.^(3,27–29) Consequently, HSP90 could strongly induce peptide-specific CTL responses *in vitro* and *in vivo* without obvious side-effects,⁽²⁰⁾ and it is intriguing that its action may surpass the benefits of IFN α .

Collectively, our present study may reflect one potential vaccination protocol. Since the vaccination protocol with




Fig. 4. Analysis of survivin-2B80-88 peptide-specific cytotoxicity. T cells of wells (a) through (h) in Figure 3 were assessed for their peptide-specific cytotoxicity against T2A24 target cells pulsed with the survivin-2B80-88 peptide and HIV peptide, and against control K562 cells. E/T, effector/target; HIV, human immunodeficiency virus.




Fig. 5. Clonal analysis of survivin-2B80-88 peptide-specific CD8 T cells. T cells in well (d) in Figure 3 were cultured and CTL clone D-13 was obtained. Subsequently, D-13 was studied for (A) tetramers and (B) cytotoxicity against T2A24 cells pulsed with survivin-2B80-88 and HIV peptides, and (C) cytotoxicity against human tumor cells (LK79, A549 and K562) that express survivin and/or HLA-A24 molecules as indicated. CTL, cytotoxic T lymphocyte; E/T, effector/target; HIV, human immunodeficiency virus; HLA, human leukocyte antigen.

survivin-2B80-88 plus IFA and IFN α appears effective in other cancers such as pancreatic cancer as well, this protocol may be useful as a standard immunotherapy modality.

Acknowledgments

This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of

Japan (grant numbers 16209013, 17016061 and 15659097), and for Practical Application Research from the Japan Science and Technology Agency and for Cancer Research (15-17 and 19-14) from the Ministry of Health, Labour and Welfare of Japan.

Disclosure Statement

The authors have no conflict of interest.

References

- 1 Van der Bruggen P, Traversari C, Chomez P *et al*. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 1991; 254: 1643-7.
- 2 Hirohashi Y, Torigoe T, Inoda S *et al*. The functioning antigens; beyond just as the immunological targets. *Cancer Sci* 2009; 100: 798-806.

- 3 Sato N, Hirohashi Y, Tsukahara T *et al*. Molecular pathologic approaches to human tumor immunology. *Pathol Int* 2009; 59: 205-17.
- 4 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. *Nature Med* 2004; 10: 909-15.
- 5 Tsukahara T, Torigoe T, Tamura Y, Kawaguchi S, Wada T, Sato N. Antigenic peptide vaccination: provoking immune response and clinical benefit for cancer. *Curr Immunol Rev* 2008; 4: 235-41.

- 6 Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. *Immunity* 1999; **10**: 281–7.
- 7 Andersen MH, Becker JC, Straten P. Regulators of apoptosis: suitable targets for immune therapy of cancer. *Nat Rev Drug Discov* 2005; **4**: 399–409.
- 8 Tsuruma T, Hata F, Torigoe T *et al*. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. *J Transl Med* 2004; **2**: 19–29.
- 9 Tsuruma T, Iwayama Y, Ohmura T *et al*. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. *J Transl Med* 2008; **6**: 24–35.
- 10 Kawaguchi S, Wada T, Ida K *et al*. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. *J Transl Med* 2005; **3**: 1–9.
- 11 Honma I, Kitamura H, Torigoe H *et al*. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. *Cancer Immunol Immunother* 2009; **58**: 1801–7.
- 12 Coulie PG, Karanikas V, Lurquin C. Cytolytic T-cell response of cancer patients vaccinated with a MAGE antigen. *Immunol Rev* 2002; **188**: 33–42.
- 13 Nagaraj S, Pisarev V, Kinarsky L *et al*. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. *J Immunother* 2007; **30**: 169–79.
- 14 Hirohashi Y, Torigoe T, Inoda S *et al*. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. *Immunotherapy* 2010; **2**: 201–11.
- 15 Nakatsugawa M, Hirohashi Y, Torigoe T *et al*. Novel spliced form of a lens protein as a novel lung cancer antigen. Lensin splicing variant 4. *Cancer Sci* 2009; **100**: 1485–93.
- 16 Honma I, Torigoe T, Hirohashi Y *et al*. Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer. *J Transl Med* 2009; **7**: 103–10.
- 17 Inoda S, Hirohashi Y, Torigoe T *et al*. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. *J Immunother* 2009; **32**: 474–85.
- 18 Sato E, Torigoe T, Hirohashi Y *et al*. Identification of immunogenic CTL epitopes of HIFPH3 for specific immunotherapy of renal cell carcinoma. *Clin Cancer Res* 2008; **14**: 6916–23.
- 19 Hirohashi Y, Torigoe T, Maeda A *et al*. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. *Clin Cancer Res* 2002; **8**: 1731–9.
- 20 Idenoue S, Hirohashi Y, Torigoe T *et al*. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. *Clin Cancer Res* 2005; **11**: 1474–82.
- 21 Hariu H, Hirohashi Y, Torigoe T *et al*. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. *Clin Cancer Res* 2005; **11**: 1000–9.
- 22 Le Bon A, Etchart N, Rossmann C *et al*. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. *Nat Immunol* 2003; **4**: 1009–15.
- 23 Dikopoulos N, Bertoletti A, Kroeger A, Hauser H, Schirmbeck R, Reimann J. Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. *J Immunol* 2005; **174**: 99–109.
- 24 Di Pucchio T, Pilla L, Capone I *et al*. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. *Cancer Res* 2006; **66**: 4943–51.
- 25 Gigante M, Mandic M, Wesa AK *et al*. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type *in vitro* T-cell responses from RCC patients. *J Immunother* 2008; **31**: 254–62.
- 26 Badovinac VP, Messingham KN, Jabbari A, Haring JS, Harty JT. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. *Nature Med* 2005; **11**: 748–56.
- 27 Kurotaki T, Tamura Y, Ueda G *et al*. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. *J Immunol* 2007; **179**: 1803–13.
- 28 Kutomi G, Tamura Y, Okuya K *et al*. Targeting to static endosome is required for efficient cross-presentation of endoplasmic reticulum-resident oxygen regulated protein 150 (ORP150)-peptide complexes. *J Immunol* 2009; **183**: 5861–9.
- 29 Okuya K, Tamura Y, Saito K *et al*. Extracellular heat shock protein 90 (Hsp90) directs self-DNA to static early endosome-resident TLR-9, leading to type I interferon production. *J Immunol* 2010; **184**: 7092–9.

Cytotoxic T Lymphocytes Efficiently Recognize Human Colon Cancer Stem-Like Cells

Satoko Inoda,^{*†‡} Yoshihiko Hirohashi,^{*}
 Toshihiko Torigoe,^{*} Rena Morita,^{*}
 Akari Takahashi,^{*} Hiroko Asanuma,[§]
 Munehide Nakatsugawa,^{*} Satoshi Nishizawa,^{*}
 Yasuaki Tamura,^{*} Tetsuhiro Tsuruma,[†]
 Takeshi Terui,[‡] Toru Kondo,[¶] Kunihiro Ishitani,[‡]
 Tadashi Hasegawa,[§] Koichi Hirata,[†]
 and Noriyuki Sato^{*}

From the Department of Pathology,^{*} First Department of Surgery,[†]
 and Division of Clinical Pathology,[§] Sapporo Medical University
 School of Medicine, Sapporo; the Higashi Sapporo Hospital,[‡]
 Sapporo; and the Team for Cell Lineage Modulation,[¶] RIKEN
 Center for Developmental Biology, Kobe, Japan

Cancer stem-like cells (CSCs) and tumor-initiating cells (TICs) are a small population of cancer cells that share three properties: tumor initiating ability, self-renewal, and differentiation. These properties suggest that CSCs/TICs are essential for tumor maintenance, recurrence, and distant metastasis. Here, we show that cytotoxic T lymphocytes (CTLs) specific for the tumor-associated antigen CEP55 can efficiently recognize colon CSCs/TICs both *in vitro* and *in vivo*. Using Hoechst 33342 dye staining, we isolated CSCs/TICs as side population (SP) cells from colon cancer cell lines SW480, HT29, and HCT15. The SP cells expressed high levels of the stem cell markers SOX2, POU5F1, LGR5, and ALDH1A1 and showed resistance to chemotherapeutic agents such as irinotecan or etoposide. To evaluate the susceptibility of SP cells to CTLs, we used CTL clone 41, which is specific for the CEP55-derived antigenic peptide Cep55/c10orf3_193 (10) (VYVKGLLAKI). The SP cells expressed HLA class I and CEP55 at the same level as the main population cells. The SP cells were susceptible to CTL clone 41 at the same level as main population cells. Furthermore, adoptive transfer of CTL clone 41 inhibited tumor growth of SW480 SP cells *in vivo*. These observations suggest that Cep55/c10orf3_193(10) peptide-based cancer vaccine therapy or adoptive cell transfer of the CTL clone is a possible approach for targeting chemotherapy-resistant colon CSCs/TICs. (*Am J Pathol* 2011, 178:1805–1813; DOI: 10.1016/j.ajpath.2011.01.004)

Colon cancer is one of the most common malignancies worldwide. With recent progress in treatment, the prognosis has improved to some extent. In advanced disease, however, the prognosis remains unfavorable, because of recurrence, distant metastasis, and resistance to treatment. Thus, novel treatment modalities are needed.

Cancers contain morphologically heterogeneous populations. This fact has led to the cancer stem cell theory,¹ the idea that cancers are composed of several types of cells, and that only a small population of cancer cells that can regenerate cancer tissues, much as normal tissue can be regenerated only by a small population of stem-like cells. Recently, cancer stem-like cells and tumor-initiating cells (CSCs/TICs) have been isolated from various types of malignancies, including colon cancer.^{2–6} In colon cancer, CSCs/TICs can reinitiate tumors that resemble mother colon cancer tissues morphologically when transplanted into immunodeficient mice.³ Furthermore, these CSCs/TICs have higher tumorigenic potential than do non-CSCs/TICs. Previous reports have shown that CSCs/TICs are resistant to a variety of treatments, including chemotherapy and radiotherapy, with varied mechanisms of resistance, including high expression of drug transporters, relative cell cycle quiescence, high levels of DNA repair machinery, and resistance to apoptosis.⁷ These reports^{3–6} support the hypothesis that malignant cancers comprise heterogeneous populations that organize in a hierarchical differentiation model. The CSCs/TICs are located at the top of this hierarchy, and targeting CSCs/TICs is essential to achieve efficient effects for treatment of malignant diseases. Recently, some trials targeting CSCs/TICs have been reported for hema-

Supported in part by a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (N.S.) and by the Program for Developing the Supporting System for Upgrading Education and Research under the Ministry of Education, Culture, Sports, Science and Technology of Japan (N.S.).

Accepted for publication January 4, 2011.

CME Disclosure: None of the authors disclosed any relevant financial relationships.

Address reprint requests to Yoshihiko Hirohashi, M.D., Ph.D., Department of Pathology, Sapporo Medical University, School of Medicine, South-1 West-17, Chuo-ku, Sapporo 060-8556, Japan. E-mail: hirohash@sapmed.ac.jp.

topoietic malignancies.⁸ Hedgehog signaling is essential for maintenance of myeloid leukemia stem cells, and inhibition of hedgehog signaling by cyclopamine is effective for imatinib-resistant myeloid leukemia.⁹ To date, however, no such CSC/TIC targeting approach has been reported for colon cancer.

In the present study, we evaluated the efficiency of CTL-based immunotherapy targeting colon CSCs/TICs. Using Hoechst 33342 dye, we isolated colon CSCs/TICs as side population (SP) cells from six colon cancer cell lines. The SP cells derived from SW480, HT29, and HCT15 showed higher tumorigenicity than did main population (MP) cells. On the other hand, SP cells from KM12LM, Lovo, and Colo320 did not show any increase in tumorigenicity, compared with MP cells. This suggests that SW480, HT29, and HCT15 SP cells (but not KM12LM, Lovo, and Colo320 SP cells) were enriched with CSCs/TICs. In RT-PCR analysis the SW480, HT29, and HCT15 SP cells showed a stem cell-like gene expression signature, including SOX2, POU5F1, LGR5, and ALDH1A1. Furthermore, these SP cells also showed resistance to chemotherapeutic agents, including irinotecan and etoposide. These observations support the idea that these SP cells had stem cell-like features. To assess the immunogenicity of SP cells, we evaluated the expression of HLA class I and of CEP55, which is a tumor-rejection antigen of breast and colon cancer.^{10,11} The SP cells expressed HLA class I (and also HLA-A24) at the same level as MP cells. The SP cells also expressed CEP55 messenger RNA (mRNA) at the same level as MP cells in RT-PCR. To confirm the susceptibility of SP cells to cytotoxic T lymphocytes (CTLs), we used CTL clone 41, which recognizes CEP55 in an HLA-A24-restricted manner.¹⁰ CTL clone 41 killed SW480, HT29, and HCT15 SP cells at the same level as it killed MP cells and presorted cells. These observations suggest that colon CSCs/TICs are also sensitive to CTLs, as non-CSC/TIC populations are. Furthermore, adoptive transfer of CTL clone 41 inhibited the tumor growth of SW480 SP cells in immunodeficient mice. These observations suggest that CTL-based colon cancer immunotherapy is efficient for colon CSCs/TICs. To our knowledge, the present study provides the first direct evidence that colon CSCs/TICs are susceptible to CTLs and thus opens possibilities for future applications in immunotherapy using CSC/TIC-specific vaccines.

Materials and Methods

Cell Lines

Colon adenocarcinoma cell lines SW480 (HLA-A*0201/2402), HCT15 (HLA-A*0201/2402), HT29 (HLA-A1/24), Lovo, and Colo320 were kind gifts of Dr. K. Imai (Sapporo, Japan), and KM12LM was a kind gift of Dr. K. Itoh (Kurume, Japan). All cell lines except K562 were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA). K562 was cultured in RPMI-1640 (Sigma-Aldrich) supplemented with 10% fetal

bovine serum. HCT15-B2M, a stable transfectant of HCT15 cells with B2M (β 2 microglobulin) cDNA, was cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 10 μ g/mL puromycin (Sigma-Aldrich).¹¹

Side Population Analysis

Side population analysis was performed as described previously, with some modifications.¹² Trypsinized cultured cells were washed with PBS and were resuspended at 37°C in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum. After 10 minutes preincubation, the cells were labeled with Hoechst 33342 dye (Lonza, Walkersville, MD) for 90 minutes at concentrations of 3.75 μ g/mL for Colo320, 5 μ g/mL for SW480 and Lovo, 7.5 μ g/mL for HT29 and KM12LM, and 10 μ g/mL for HCT15, with or without verapamil (Sigma-Aldrich), which is an inhibitor of ABC transporters, at concentrations of 50 μ mol/L for SW480, HCT15, and Colo320, 75 μ mol/L for Lovo, and 100 μ mol/L for HT29. Cells were counterstained with 1 μ g/mL propidium iodide to label dead cells. Next, 1×10^6 viable cells were analyzed and sorted using a BD FACSAria II fluorescence-activated cell sorting system (BD Biosciences, Franklin Lakes, NJ). The Hoechst dye was excited at 355 nm, and its fluorescence was measured at two wavelengths using optical filters 405 DF20 [450/20 nm band-pass filter O (Hoechst Blue)] and 635LP [635 nm long-pass edge filter (Hoechst Red)]. Propidium iodide labeling was measured through a 630/BP30 filter for discrimination of dead cells.

Xenograft Model

The SP cells, MP cells, and presorted cells from colon cancer cell lines were mixed 1:1 by volume with Matrigel (BD Biosciences) and were injected subcutaneously into the backs of female 4- to 8-week-old nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Tumor size in cubic millimeters was assessed weekly with calipers and was calculated as Tumor Size = (Longest Diameter \times Shortest Diameter²)/2.

RT-PCR Analysis of SP and MP Cells

RT-PCR analysis was performed as described previously.¹⁰ Total RNAs were isolated from both SP cells and MP cells using an RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. Complementary DNA (cDNA) was synthesized from 2 μ g of total RNA by reverse transcription using SuperScript III reverse transcriptase (Invitrogen). The PCR amplification was performed in 20 μ L of PCR mixture containing 1 μ L of cDNA mixture, 0.5 μ L of Taq DNA polymerase (Qiagen) and 4 pmol of primers. The PCR mixture was initially incubated at 98°C for 2 minutes, followed by 30 cycles of denaturation at 98°C for 15 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 30 seconds. The following primer pairs were used for RT-PCR analysis (forward and reverse, respectively): 5'-CATGATG-

GAGACGGAGCTGA-3' and 5'-ACCCCGCTCGCCATGC-TATT-3' for SOX2, with an expected PCR product size of 410 bp; 5'-TGGAGAAGGAGAAGCTGGAGCAAAA-3' and 5'-GGCAGATGGTCTGTTGGCTGAATA-3' for POU5F1, with an expected PCR product size of 163 bp; 5'-CTCTT CCTCAAACCGTCTGC-3' and 5'-GATCGGAGGCTA-AGCAACTG-3' for LGR5, with an expected PCR product size of 181 bp; 5'-TGTTAGCTGATGCCGACTTG-3' and 5'-TTCTTAGCCCGCTCAACACT-3' for ALDH1A1, with an expected PCR product size of 154 bp; 5'-TGAGTTT-GCCATCACAGAGC-3' and 5'-TTGCTTGCTGGTGCAT-TAAC-3' for CEP55, with an expected PCR product size of 521 bp; and 5'-ACCACAGTCCATGCCATCAC-3' and 5'-TCCACCACCCTGTTGCTGTA-3' for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), with an expected product size of 452 bp. GAPDH was used as an internal control.

Quantitative Real-Time PCR Analysis

Quantitative real-time PCR was performed using an ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. Primers and probes were designed by the manufacturer (TaqMan gene expression assays; Applied Biosystems). Thermal cycling was performed using 40 cycles of 95°C for 15 seconds followed by 60°C for 1 minute. Each experiment was done in triplicate, with normalization to the *GAPDH* gene as an internal control.

Flow Cytometric Analysis and Monoclonal Antibodies

Cells were incubated with mouse monoclonal antibodies at saturation concentration for 30 minutes on ice, washed with PBS, and stained with a polyclonal goat anti-mouse antibody coupled with fluorescein isothiocyanate for 30 minutes. Samples were analyzed using a BD FACSCalibur flow cytometry system (Becton Dickinson, Mountain View, CA). Anti-pan HLA class I (W6/32) and anti-HLA-A24 monoclonal antibodies (C7709A2.6 hybridoma, a kind gift from Dr. P.G. Coulie, Brussels, Belgium) were prepared from hybridomas.

Survival Studies for Etoposide and Irinotecan

We isolated SP and MP cells of SW480 and HCT15 and seeded them into 96-well culture plates at 1×10^4 cells per well for each population of cells. The cells in both populations were treated with etoposide (1 and 5 $\mu\text{g}/\text{mL}$) or irinotecan (40 and 400 $\mu\text{g}/\text{mL}$ for SW480, 10 and 100 $\mu\text{g}/\text{mL}$ for HCT15). After 72 hours of exposure to the chemotherapeutic agents, viability of the cells was determined using the SOD assay kit WST-1, which was performed according to the manufacturer's protocol (Dojindo Molecular Technologies, Kumamoto, Japan; Rockville, MD).

Cytotoxicity Assay for SP Cells with CTL Clone 41

We had previously established CTL clone 41, which recognizes an HLA-A24 restricted antigenic peptide (VYVK-GLLAKI) termed Cep55/c10orf3_193(10), from an HLA-A24-positive breast cancer patient's peripheral blood mononuclear cells.⁸ The lytic activity of CTL clone 41 for SP cells, MP cells, and presorted cells was evaluated by ⁵¹Cr release assay. Briefly, SP cells, MP cells and presorted cells were labeled with 100 μCi of ⁵¹Cr for 1 hour at 37°C, washed four times with PBS, and resuspended in AIM-V medium (Invitrogen). The ⁵¹Cr-labeled target cells (2000 cells/well) were then incubated with various numbers of effector cells for 6 hours at 37°C in 96-well culture plates. Radioactivity of the culture supernatant was measured with a gamma counter. The percentage of cytotoxicity was calculated as follows: % Specific Lysis = (Experimental Release - Spontaneous Release) \times 100 / (Maximum Release - Spontaneous Release). Target cells were treated with 100 units/mL interferon- γ for 48 hours before the assay.

Winn Assay

SW480 SP cells were mixed with CTL clone 41 at a ratio of 1 SP cell to 10 CTL cells. The resulting mixture (200 μL with 1×10^6 CTL clone 41 and 1×10^5 SP cells) was injected subcutaneously into the backs of NOD/SCID mice. A control group of five mice was injected with SP cells alone. Tumor size was assessed weekly.

CTL Adoptive Transfer

NOD/SCID mice were inoculated subcutaneously on the back with 1×10^3 SW480 SP cells. Three weeks later, when the tumor started to be palpable, 5×10^4 Cep55/c10orf3_193(10)-specific CTL clone cells or PBS was injected intravenously. The same adoptive transfer procedure was performed 4 weeks after inoculation with SP cells. Tumor size was assessed weekly.

Statistical Analysis

In the xenograft model, survival studies using chemotherapeutic agents, cytotoxicity assay, Winn assay, and adoptive transfer model, the data were analyzed using the Mann-Whitney *U*-test, with $P < 0.05$ conferring statistical significance.

Results

Isolation of Colon CSCs/TICs as SP Cells

Several methods to isolate colon cancer CSCs/TICs has been reported, including cell surface markers such as CD44 or PROM1 (CD133), SP cells, and the Aldefluor assay.^{3-6,13} In the present study, we isolated colon CSCs/TICs using SP cell analysis. Several colon cancer cell lines were dyed with Hoechst 33342 and then analyzed with a BD FACSAria II flow cytometer as




Figure 1. Isolation of colon CSCs/TICs from colon cancer cell lines and tumor growth of the SP cells. **A:** Colon cancer cell line SW480 was stained with Hoechst 33342 dye as described under *Materials and Methods*, with or without verapamil. Stained cells were analyzed using a BD FACSAria II fluorescence-activated cell sorting system. Frequency of SP cells was 3.3%. **B:** Colon cancer cell lines (HT29, HCT15, KM12LM, Lovo, and Colo320) were stained with Hoechst 33342 dye with or without verapamil. Stained cells were analyzed using a BD FACSAria II system. Frequencies of SP cells ranged from 9.1% for KM12LM cells to 11.1% for HCT15 cells. **C:** SP cells, MP cells, and presorted cells of colon cancer cell lines SW480, HT29, and HCT15 were inoculated subcutaneously into the backs of NOD/SCID mice (1×10^5 cells injected). Data are reported as means \pm SD. *P* values indicate differences between cell types according to a Mann-Whitney *U*-test. **D:** Representative tumor growth in NOD/SCID mice at the SP cell injection site (1×10^5 cells injected). SP cells and MP cells were inoculated subcutaneously into the left and right side of the back, respectively.

described under *Materials and Methods*. Side population cells could be detected in all six colon cancer cell lines analyzed (ie, SW480, HT29, HCT15, Colo320, Lovo, and KM12LM) (Figure 1, A and B). The frequency of SP cells ranged from 3.3% for SW480 to 11.1% for HCT15 cells. All these SP cells were specifically inhibited by verapamil, as has been shown previously,¹⁴ suggesting that these SP cells were specific for ABC transporter expression. Because previous studies showed that some colon cancer SP cells were not enriched with a CSC/TIC population,¹⁵ it was essential to confirm the presence of CSCs/TICs in SP cells for further analysis. We inoculated these SP cells subcutaneously into the back of immunodeficient NOD/SCID mice using serial dilution. The SP cells derived from SW480, HCT15, and HT29 showed higher tumor initiating ability, compared with MP cells (Table 1). Furthermore, SW480, HT29, and HCT15 SP cells showed faster tumor growth, compared with MP cells (Figure 1, C and D), suggesting the presence of CSCs/TICs in these SP cells. In contrast, the SP cells derived from Colo320, Lovo, and KM12LM did not show any difference in tumorigenicity or tumor growth, compared with MP cells. We therefore restricted further analysis to the SW480, HT29, and HCT15 SP cells as colon cancer CSCs/TICs.

RT-PCR Analysis of Colon Cancer SP Cells

To examine the molecular properties of SP cells, we performed RT-PCR analysis. SOX2 and POU5F1 are representative markers for embryonal stem cells and CSCs/TICs.¹⁶ The SP cells derived from SW480, HT29, and HCT15 showed higher expression of both SOX2 and POU5F1, compared with MP cells (Figure 2A). ALDH1A1, a colon CSC/TIC marker,⁶ was expressed at a higher level in SP cells of HCT15 than in MP cells, but SP cells of SW480 and HT29 did not show any difference in comparison with MP cells. SW480 and HT29 SP cells also showed higher expression of LGR5, which is known as a normal colon stem cell marker.¹⁷ To confirm the expression of stem cell markers, we also performed real-time PCR. The SW480 SP cells expressed 90 times higher SOX2, 7 times higher POU5F1, 153 times higher LGR5, and 6.1 times higher ALDH1A1, compared with MP cells (Figure 2B). These findings indicate that these SP cells had molecular properties similar to those of embryonal stem cells.

Resistance to Chemotherapeutic Reagents

Although SP cells derived from liver cancer cell line HuH7 have showed resistance to chemotherapy,¹³ we know of no conclusive previous studies of such resistance in co-

Table 1. Tumor Initiating Ability of Colon Cancer SP Cells

| Cell line (% SP cells) | Tumor initiating ability* | | |
|---------------------------|---------------------------|----------------------|----------------------|
| | 1 × 10 ⁴¹ | 1 × 10 ³¹ | 1 × 10 ²¹ |
| SW480 (3.3) | | | |
| SP cells | 4/4 | 4/6 | 4/4 |
| MP cells | 2/4 | 3/5 | 0/4 |
| HT29 (10.4) | | | |
| SP cells | 3/3 | 2/3 | 3/3 |
| MP cells | 3/3 | 0/3 | 0/3 |
| HCT15 (11.1) | | | |
| SP cells | 3/3 | 3/4 | 3/3 |
| MP cells | 1/3 | 1/4 | 0/3 |
| Colo320 (10.9) | | | |
| SP cells | 2/2 | 1/2 | 1/2 |
| MP cells | 2/2 | 2/2 | 1/2 |
| Lovo (9.3) | | | |
| SP cells | 0/1 | 1/1 | 0/1 |
| MP cells | 1/1 | 0/1 | 0/1 |
| KM12LM (9.1) | | | |
| SP cells | 1/2 | 2/2 | 1/1 |
| MP cells | 1/2 | 2/2 | 1/1 |

MP, main population; SP, side population.

*Tumor initiating ability is expressed as the ratio of tumor-initiation to injection.

[†]The tumor initiation abilities were evaluated at day 42 after injection of the indicated number of cells.

ion SP cells. We performed a cell survival study of colon cancer SP cells using the chemotherapeutic agents irinotecan and etoposide. The SW480 and HCT15 SP cells were more resistant to both irinotecan and etoposide than were MP cells (Figure 3, A and B). This finding is consistent with findings for CSCs/TICs derived from other organs.^{22,24}

Expression of HLA and Tumor-Associated Antigens in SP Cells

Because CTLs recognize tumor-associated antigen (TAA)-derived antigenic peptides presented by HLA class I molecules, expression of HLA class I molecules is essential for activation of CTLs. Several types of malignancies have been reported to lose the expression of HLA class I molecules through various mechanisms and so escape CTL attack.¹⁸ We therefore evaluated the expression of HLA class I molecules and TAA. We assessed the differences of HLA class I and HLA-A24 expression between SP cells and MP cells by flow cytometry. Because ELISA study has revealed that HCT15 cells lack B2M because of gene mutations of *B2M*,¹⁹ we transduced wild-type B2M cDNA into HCT15 cells and so established HCT15-B2M cells. The SW480, HT29, and HCT15-B2M SP cells showed HLA class I and HLA-A24 expression at the same level as MP cells (Figure 4, A and B). Furthermore, we assessed the expression of one of the colon cancer TAAs, CEP55, by both RT-PCR and real-time PCR (Figure 2, A and B). Both SP cells and MP cells derived from SW480, HT29, and HCT15-B2M expressed CEP55 mRNA at the same level. These data raised the possibility that SP cells are also sensitive to CTLs specific for the CEP55-derived antigenic peptide. Because both SP cells and MP cells expressed CEP55 mRNA at the same level, this appeared

to be an ideal target for comparing the susceptibilities of SP cells and MP cells to CTLs.

Susceptibility of CSCs/TICs to CTLs, in Vitro and in Vivo

We had previously established CTL clone 41, which is specific for the cancer-related, antigen-derived, HLA-A24-restricted peptide Cep55/c10orf3_193(10).¹⁰ CTL clone 41 recognized CEP55-positive and HLA-A24-positive cancer cells, as described previously.^{10,11} In the present study, we used a ⁵¹Cr release assay to examine whether CTL clone 41 can recognize SP cells. All SP cells derived from SW480, HT29, and HCT15-B2M showed susceptibility to CTL clone 41 at the same level as the MP cells and the presorted bulk cell lines (Figure 4C). This indicates that the colon CSCs/TICs were sensitive to CTLs.

To analyze the cytotoxic activity of the CTL clone *in vivo*, we performed a Winn assay. SW480 SP cells with or without CTL clone 41 were injected into the backs of NOD/SCID mice subcutaneously. CTL clone 41 significantly inhibited the tumorigenicity of SW480 SP cells (Figure 4D). Because CTLs were injected at the same time and place as the SP cells in the Winn assay, we could not rule out the possibility that SP cells were killed *in vitro*. We




Figure 2. Expression of stem cell markers in SP and MP cells. **A:** mRNAs purified from SW480, HT29, and HCT15 SP and MP cells were analyzed by RT-PCR. **B:** mRNA purified from SW480 SP cells and MP cells were analyzed with real-time PCR. mRNA expression level is relative to MP cells. Data are reported as means ± SD.




Figure 3. Sensitivity to chemotherapeutic agents. SP cells and MP cells derived from SW480 and HCT15 were incubated in the presence of irinotecan (CPT-11) (A) or etoposide (VP-16) (B) for 3 days. After incubation, the cell viabilities were measured by WST-1 assay. Data are reported as means \pm SD. Differences between SP cells and MP cells were examined for statistical significance using the Mann-Whitney *U*-test.

therefore used an adoptive transfer model, as described under *Materials and Methods*. SW480 SP cells were inoculated into the back of NOD/SCID mice subcutaneously. Three weeks later, after confirmation of palpable tumors, CTLs were injected intravenously. Tumors of CTL-injected mice were significantly inhibited in growth, compared with tumors of control mice (Figure 4E). These data indicate that CTLs could recognize CSCs/TICs both *in vitro* and *in vivo*.

Discussion

In the present study, we successfully isolated colon cancer CSCs/TICs as SP cells, using Hoechst 33342 staining. Side population cells were first described by Goodell et al,¹² and CSCs/TICs of several types of malignancies were successfully isolated as SP cells in subsequent studies.^{14,20–24} Haraguchi et al¹³ isolated SP cells from

gastrointestinal cancer cell lines; they reported the gene expression profiles and resistance to chemotherapeutic agents of SP cells derived from liver cancer cell line Huh7, but did not determine their tumorigenicity. Burkert et al¹⁵ found that SP cells derived from gastrointestinal cancers cell lines HT29, HGT101, Caco2, and HRA19a1.1 were not enriched with a CSC/TIC population. In the present study, we were able to isolate SP cells from all six colon cancer cell lines studied (SW480, HT29, HCT15, KM12LM, Lovo, and Colo320). However, in only three of the six cell lines did the SP cells show higher tumorigenicity than MP cells, suggesting that these SP cells were enriched with CSC/TIC populations. Thus, SP cells might not be the definitive phenotype of CSCs/TICs, and confirmation of tumorigenicity in immunodeficient mice is essential for validation of SP cells as a source of CSCs/TICs. In the present study, the SP cells derived from SW480, HCT15, and HT29 cells were confirmed to be enriched with CSCs/TICs. Furthermore, these SP cells expressed stem cell markers, including SOX2, POU5F1 and LGR5, at higher levels than MP cells, suggesting correspondence with CSCs/TICs. Thus, these SP cells would be a useful tool for analysis of colon CSCs/TICs.

In the present study, we evaluated the immunogenicity of colon CSCs/TICs. Colon cancer CSCs/TICs expressed HLA class I molecules, and also CEP55, which is one of the TAAs. Furthermore, colon CSCs/TICs expressed several other TAA-encoding genes (data not shown), including BIRC5 (encoding apoptosis inhibitor survivin), BIRC7 (encoding livin), WT1, CTAG1B (alias *NY-ESO-1*), and MAGEA4. As a novel finding, colon cancer CSCs/TICs were sensitive to CTLs both *in vitro* and *in vivo*. Recently, Todaro et al²⁵ showed that colon CSCs/TICs were sensitive to $\gamma\delta$ T cells. Because both CTLs and $\gamma\delta$ T cells kill target cells through secretion of perforin (encoded by the *PRF1* gene) and granzyme B (encoded by *GZMB*), these observations strongly suggest that CSCs/TICs are sensitive to PRF1- and GZMB-dependent apoptosis. Todaro et al²⁶ had earlier reported that PROM1-positive (CD133⁺) colon cancer CSCs/TICs secrete IL-4 in an autocrine manner and upregulate the antiapoptotic proteins CFLAR (c-FLIP), BCL2L1 (Bcl-xL), and PEA15 (PED), thereby gaining resistance to chemotherapeutic agents. Saigusa et al²⁷ reported that distant recurrence of rectal cancer after chemotherapy was related to the expression of CSC/TIC markers such as PROM1 (CD133), POU5F1 (Oct3/4), and SOX2. These reports support the idea that colon CSCs/TICs are resistant to apoptotic cell death. The fact that immunocytes induce apoptosis in their target cells raises the question of whether colon CSCs/TICs are also sensitive to immunotherapy.

In the present study, and in that of Todaro et al,²⁵ colon CSCs/TICs were sensitive to perforin- and granzyme B-dependent apoptosis. Thus, both CTLs and $\gamma\delta$ T cells can be useful tools for colon CSC/TIC targeting therapy. However, because $\gamma\delta$ T cells do not recognize target cells in an antigen-specific manner, immunotherapy using $\gamma\delta$ T cells should also recognize the non-CSC/TIC population. Because the number of $\gamma\delta$ T cells is restricted *in vivo*, it may be in doubt whether $\gamma\delta$ T cell can recognize colon




Figure 4. Immunogenicity of SP cells. **A:** Expression of HLA class I molecules. SW480, HT29, and HCT15-B2M SP cells and MP cells were stained with an anti-pan HLA class I monoclonal antibody (W6/32), then with a fluorescein isothiocyanate (FITC)-labeled secondary antibody. Stained cells were analyzed with a BD FACSCalibur cell sorting system. Solid profiles represent isotype control as the primary antibody. **B:** Expression of HLA-A24 molecule. SW480, HT29, and HCT15-B2M SP cells and MP cells were stained with an anti-HLA-A24 monoclonal antibody (C7709A2.6), then an FITC-labeled secondary antibody. Stained cells were analyzed with a FACSCalibur cell sorting system. Solid profiles represent isotype control as primary antibody. **C:** Cytotoxicity of CTL. clone 41. A ⁵¹Cr release assay was performed using CTL clone 41 at several effector/target ratios. SW480, HT29, and HCT15-B2M SP cells, MP cells, and presorted cells were used for assay; K562 cells were used as a negative control. Data are reported as means ± SD. **D:** Winn assay. SW480 SP cells (1 × 10⁵) were inoculated subcutaneously into the backs of NOD/SCID mice with or without CTL clone 41 cells (1 × 10⁶). Data are reported as means ± SD. Differences between SP cells and SP cells + CTL were examined for statistical significance using the Mann-Whitney *U*-test. **E:** Adoptive transfer model. SW480 SP cells (1 × 10⁵) were inoculated subcutaneously into the back of NOD/SCID mice. At 3 and 4 weeks later, CTL clone 41 or PBS was injected intravenously with or without CTL clone 41 cells (1 × 10⁶). Data are reported as means ± SD. Differences were examined for statistical significance using the Mann-Whitney *U*-test.

cancer CSCs/TICs *in vivo* efficiently. Recently, based on a large cohort study, Ogino et al²⁸ reported that lymphocytic reaction to tumor was associated with longer survival of colorectal cancer patients. They did not analyze the subtypes of infiltrating lymphocytes; however, the findings from this large-scale study strongly support the notion that immune reaction to tumor cells is important for control of the disease.

Wei et al²⁹ reported recently that glioma-derived CSCs/TICs suppressed T-cell proliferation and activation, and induced T-cell apoptosis through expression of co-stimulatory inhibitory molecule CD274 (B7-H1) and soluble LGALS3 (galectin-3); glioma CSCs/TICs enhance the induction of regulatory T cells. We also observed that SW480 SP cells express higher mRNA of the immunosuppressive cytokine IL-10 than MP cells (data not

shown). Thus, colon CSCs/TICs may have immunosuppressive potential and so inhibit CTL induction. However, colon CSCs/TICs are efficiently killed by CTLs, and colon CSCs/TICs have no influence on the effector phase of CTLs. Thus, adoptive cell transfer of CSC/TIC-specific CTL clones, T-cell-receptor-induced T cells, or peptide vaccination accompanied by an anti-IL-10 monoclonal antibody might be an effective approach for eliminating colon CSCs/TICs.

In the present study, we observed that both colon CSCs/TICs and non-CSCs/TICs were sensitive to CEP55-specific CTLs at the same level. This finding seems reasonable, given that CSCs/TICs express CEP55 mRNA at the same level. Huge numbers of TAAs have already been reported,^{30,31} and the next challenge is to identify which TAAs would be the most suitable targets for cancer immunotherapy. According to the manner of expression in CSCs/TICs and non-CSCs/TICs, TAAs can be classified into three categories: i) CSC/TIC-specific antigens, such as SOX2 and ALDH1A1; ii) non-CSC/TIC-specific antigens; and iii) shared antigens, such as CEP55.³² The frequencies of colon CSCs/TICs are 1% to 10%, and in the present study these cells had 10- to 100-fold higher tumorigenicity than non-CSCs/TICs. It is likely, therefore, that 1% to 10% of colon CSC/TIC populations have almost the same tumorigenic potential as 90% to 99% of the non-CSC/TIC population. To achieve a complete cure of the disease, shared antigens seem to be a reasonable candidate strategy. *In vivo*, however, CTL numbers are limited. Given that 1 L of peripheral blood contains approximately 5×10^9 lymphocytes, there are approximately 5×10^8 CD8 T cells in 1 L of peripheral blood and approximately 3×10^9 CD8 cells in the total volume of peripheral blood in a human adult. If the CTL precursor frequency reaches 0.1% of CD8 T cells in a patient receiving peptide vaccination therapy, then the total peptide-specific CTLs can be calculated as 3×10^6 cells in whole blood. This is not an inconsiderable number. Visible tumors as large as 1 cm diameter contain 1×10^9 tumor cells, and the estimated effector/target ratio (E/T) *in vivo* is 0.003. This ratio may be too low to expect an anti-tumor effect *in vivo*. However, if we focus only on CSCs/TICs, then the effector/target ratio will be improved. For targeting CSCs/TICs with 1% frequency, the effector/target ratio is correspondingly improved (E/T = 0.3). Thus, focusing only on the CSC/TIC population with CSC/TIC-specific antigens seems to be a better approach for advanced cancer cases. For prevention of disease recurrence after treatment, the target cells are likely to be limited, so shared antigens might be a reasonable choice for cancer immunotherapy.

Recently, some research groups have reported that monoclonal antibodies for insulin-like growth factor-1 receptor (IGF-1R), δ -like 4 ligand (DLL4), and CD47 efficiently eliminate colon cancer and leukemia CSCs/TICs.^{33–36} These approaches are also fascinating, and a reasonable option for elimination of CSCs/TICs. An antibody is a relatively stable protein, but the half-life in peripheral blood is approximately 2 to 3 weeks, and therefore serial administration is needed to maintain the effects of the antibody. On the other hand, antigenic pep-

tide vaccination can induce specific CTLs as memory cells *in vivo*, such that the specific immunity will last for several years. Thus, peptide vaccination therapy may also be useful for prevention of post-treatment cancer recurrence.

In conclusion, we report here the novel finding that colon cancer CSCs/TICs are as sensitive to CTLs as are non-CSCs/TICs, and that CEP55, a tumor-associated antigen, is a suitable antigen for targeting colon cancer CSCs/TICs.

Acknowledgments

We thank Drs. Kohzoh Imai, Kyogo Itoh, and Pierre G. Coulie for kindly providing cell lines.

References

1. Papailiou J, Bramis KJ, Gazouli M, Theodoropoulos G: Stem cells in colon cancer. A new era in cancer theory begins. *Int J Colorectal Dis* 2011, 26:1–11
2. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM: Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. *Cancer Res* 2006, 66:9339–9344
3. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF: Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci USA* 2007, 104:10158–10163
4. O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 2007, 445:106–110
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R: Identification and expansion of human colon-cancer-initiating cells. *Nature* 2007, 445:111–115
6. Huang EH, Hynes MJ, Zhang T, Ginstier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res* 2009, 69:3382–3389
7. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. *Nat Rev Cancer* 2005, 5:275–284
8. Low JA, de Sauvage FJ: Clinical experience with Hedgehog pathway inhibitors. *J Clin Oncol* 2010, 28:5321–5326
9. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA, Reya T: Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia [Erratum appeared in *Nature* 2009, 460:652]. *Nature* 2009, 458:776–779
10. Inoda S, Hirohashi Y, Torigoe T, Nakatsugawa M, Kiriya K, Nakazawa E, Harada K, Takasu H, Tamura Y, Kamiguchi K, Asanuma H, Tsuruma T, Terui T, Ishitani K, Ohmura T, Wang Q, Greene MI, Hasegawa T, Hirata K, Sato N: Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. *J Immunother* 2009, 32:474–485
11. Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, Nakatsugawa M, Tamura Y, Kamiguchi K, Tsuruma T, Terui T, Ishitani K, Hashino S, Wang Q, Greene MI, Hasegawa T, Hirata K, Asaka M, Sato N: The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. *Exp Mol Pathol* 2011, 90:55–60
12. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating *in vivo*. *J Exp Med* 1996, 183:1797–1806
13. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M: Characterization of a side population of cancer cells from human gastrointestinal system. *Stem Cells* 2006, 24:506–513
14. Murase M, Kano M, Tsukahara T, Takahashi A, Torigoe T, Kawaguchi S, Kimura S, Wada T, Uchihashi Y, Kondo T, Yamashita T, Sato N: Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. *Br J Cancer* 2009, 101:1425–1432

15. Burkert J, Otto WR, Wright NA: Side populations of gastrointestinal cancers are not enriched in stem cells. *J Pathol* 2008, 214:564–573
16. Tysnes BB: Tumor-initiating and -propagating cells: cells that we would like to identify and control. *Neoplasia* 2010, 12:506–515
17. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP: Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. *Proc Natl Acad Sci USA* 2008, 105:13427–13432
18. Campoli M, Ferrone S: HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. *Oncogene* 2008, 27:5869–5885
19. Bicknell DC, Rowan A, Bodmer WF: Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. *Proc Natl Acad Sci USA* 1994, 91:4751–4755
20. Kondo T, Setoguchi T, Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. *Proc Natl Acad Sci USA* 2004, 101:781–786
21. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. *Hepatology* 2006, 44:240–251
22. Ho MM, Ng AV, Lam S, Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. *Cancer Res* 2007, 67:4827–4833
23. Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V, Yamashita S: Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. *Endocrinology* 2007, 148:1797–1803
24. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. *Cancer Res* 2007, 67:3716–3724
25. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G, Salerno A, Dieli F, Stassi G: Efficient killing of human colon cancer stem cells by gamma-delta T lymphocytes. *J Immunol* 2009, 182:7287–7296
26. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. *Cell Stem Cell* 2007, 1:389–402
27. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C, Kusunoki M: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. *Ann Surg Oncol* 2009, 16:3488–3498
28. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. *Clin Cancer Res* 2009, 15:6412–6420
29. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Sawaya R, Lang FF, Heimberger AB: Glioma-associated cancer-initiating cells induce immunosuppression. *Clin Cancer Res* 2010, 16:461–473
30. Hirohashi Y, Torigoe T, Inoda S, Kobayashi J, Nakatsugawa M, Mori T, Hara I, Sato N: The functioning antigens: beyond just as the immunological targets. *Cancer Sci* 2009, 100:798–806
31. Sato N, Hirohashi Y, Tsukahara T, Kikuchi T, Sahara H, Kamiguchi K, Ichimiya S, Tamura Y, Torigoe T: Molecular pathological approaches to human tumor immunology [Erratum appeared in *Pathol Int* 2009, 59:900]. *Pathol Int* 2009, 59:205–217
32. Hirohashi Y, Torigoe T, Inoda S, Takahashi A, Morita R, Nishizawa S, Tamura Y, Suzuki H, Toyota M, Sato N: Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. *Immunotherapy* 2010, 2:201–211
33. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, Samuel S, Kim MP, Lim SJ, Ellis LM: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. *Cancer Res* 2009, 69:1951–1957
34. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J, Gurney A: DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. *Cell Stem Cell* 2009, 5:168–177
35. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL: CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. *Cell* 2009, 138:286–299
36. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL: CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. *Cell* 2009, 138:271–285

道医シリーズ第47篇(生涯教育シリーズXIX)

がん治療の新たな展開

監修/札幌医科大学医学部臨床検査医学講座教授
北海道医師会常任理事

渡邊直樹

3452

北海道医師会

がん治療の新たな展開

4. 癌ワクチン・免疫療法の 実際と展望

札幌医科大学医学部外科学第一講座
*札幌医科大学医学部病理学第一講座

平田公一
九富五郎
奥谷浩一
亀嶋秀和
鶴間哲慶
齋藤和俊
久木田晴彦*
鳥越俊彦*
佐藤昇志*

要旨

最近の約4分の1世紀における腫瘍免疫学の進歩は目覚ましく、免疫療法の臨床応用に広く工夫がみられている。その代表的な背景として、免疫細胞の分離・培養・増殖・活性化などによるin vitroでの修飾化技術の向上、腫瘍細胞上の標的分子の特定とその抗体による細胞傷害作用・MHCクラスIあるいはII上に結合するがん抗原の特定とそれを認識するCTLの活性化および抗腫瘍作用の確認、などについては飛躍的な進歩がみられるに至っている。その過程で免疫細胞療法が実臨床の場へ提案され、1980年代初めにNIHがCTLを用いた免疫細胞療法の臨床研究を認可して以来、同法を応用した臨床研究の爆発的普及がみられている。

日本でも1980年代半ばよりLAK T細胞を用いた養子免疫療法の普及がみられ、さらに樹状細胞を用いた免疫細胞療法が加わり、各種固型がんや血液腫瘍に対する臨床試験が高度先進医療として実施されてきた。結果的には、際立った効果を得たという十分な結果は得られていない。本邦での免疫学的治療法については上記の動きが主流で先行し、がん特異的ワクチン療法を目的としたがん抗原の探究研究の動きはごく少数の研究者に限られた時期があった。しかし、近年では、次々に数多くのがん特異的抗原の同定が進み、それにともないphase I臨床研究が数多く成されている。また同法における免疫逃避機

構と、その機構に対する解決策が徐々に明らかになり、それを試みる臨床研究も行われるに至っている。

今後は手術後の補助療法としての再発・転移予防策への応用に大きな期待が寄せられている。また、免疫細胞療法、ワクチン療法に共通して言えることは毒性や有害事象については、さほど重篤な事例が発生しないことである。今後の一層の研究展開に期待がもたれている領域といえよう。

はじめに

免疫療法において、細胞障害性T細胞 (cytotoxic T lymphocyte:CTL) の高い認識システムを確立するにあたって、がんペプチドワクチンはその中核を成す分子である。すなわち、がんペプチドはCTLの機能を有効に発揮させる役割を果たす。また腫瘍組織内やがん性胸水中の腫瘍浸潤リンパ球 (tumor infiltrating lymphocyte: TIL) の局所での増殖を可能にすることで、免疫作用機序がin situにおける自然な形で増幅可能となった^{1,2)}。すなわち抗原とCTLを制御・修飾することにより、強い腫瘍排除機構の構築を可能にしようことが明らかにされつつある。

分子生物学的制御法とその臨床応用が広く研究されている今日、大きな期待の寄せられている抗原分子は数多く、続々と臨床試験が行なわれている。多くのワクチンの抗原分子の構造が明らかにされ、そのkeyともなるペプチド形成にかかわる遺伝子構造も把握されるに至っており、人工的にペプチド分子を造り出すことが可能となり³⁾、実践的ながん治療法としての発展に期待が寄せられている。

1. がんペプチドワクチンの作用機構

がんペプチドワクチン療法は、T細胞による免疫学的制御法のひとつとして能動免疫制御法のひとつとして存在する。T細胞はその機能によって分類され、なかでもヒトがん細胞が提示するがん抗原認識リセプターを有するT細胞をCTLと総称し、CD8陽性細胞として捉えられ、ヘルパーT細胞であるCD4陽性細胞からのサイトカインなどの刺激によってその機能が促進されることが知られている⁴⁾。前者は




図1 腫瘍細胞の認識・排除機構

human lymphocyte antigen (HLA) クラス I 拘束性に、後者はクラス II 拘束性にがん抗原を認識することが明らかになっている⁵⁾。

がん抗原については、がん細胞が一定の配列の蛋白あるいはミスフォールディングにて誤った配列の蛋白を過剰に産生し、その蛋白がプロテオソーム内でペプチドレベル (アミノ酸数として8~10個) にまで分解され、そのがん抗原が小胞体に輸送され、そこでHLAクラス I と複合体を形成し、細胞表面上に出す (図1)⁶⁾。このようにがん細胞膜表面上のHLAクラスはペプチド (がん抗原を含む) によって占拠される状態にあると言え、その抗原をCD8T細胞 (CTL) が認識するわけである (図1)⁷⁾。この8~10個のペプチドがT細胞ワクチンとも言えるものである。

このようにペプチドは細胞内蛋白に由来することから、それらを産生する細胞に対する認識・識別機構が生体に存在し、その中ががん固有のペプチド (がん抗原) が存在しうるのである。このようながん治療は、人体にとっては生理的機序を応用するもので、在り方としては望ましい治療手段と考えられる。

CD8陽性T細胞はT細胞受容体 (TCR) を介して、MHCクラス I・抗原ペプチド複合体からの第1シグナルと、CD28/CD80, 86, CD40L/CD40などの相互作用による第2シグナルによって活性化CTLとなる (図2)⁸⁾。MHCクラス II・抗原ペプチド複合体から抗原刺激を受けたCD4陽性T細胞は、サイトカイン刺激によってTh1細胞とTh2細胞に分化する⁹⁾。Th1細胞はIL-2などのサイトカインを産生し、CTL活性化に関与する。以上のように、DC上のMHCクラス I・抗原ペプチド複合体からペプチド刺激を認識したCD8陽性T細胞は、ヘルパー T細胞の作用も加わり活性化CTLとなり、腫瘍抗原特異的に腫瘍細胞を攻撃・破壊する。

がんペプチドワクチン療法においては、ワクチンとして体内投与されたペプチドはDCに取り込まれ、




図2 DC機能への影響因子

表1 腫瘍免疫エスケープ機構

A. 腫瘍側の因子

- MHC重鎖欠失
- β2ミクログロブリン欠失
- 抗原分子の欠失
- TAP欠失
- LMP欠失
- Fasリガンド発現
- 免疫制御分子 (TGFβなど) の放出

B. CTL側の因子


- T細胞受容体シグナル伝達異常
- Th1/Th2バランスの喪失
- T細胞欠失
- キラー細胞抑制受容体の発現
- TregによるT細胞制御

加工をほとんど受けることなく高率にMHCクラス I 分子上に抗原提示され、ペプチド特異的なCTLを活性化する¹⁰⁾。ワクチンとして投与されたペプチドは、標的とするがん細胞がMHCクラス I 分子上に提示しているがん抗原と同一であるので、ペプチドにより活性化されたCTLはがん細胞上のがん抗原 (ペプチド) 同様に認識し、がん細胞傷害作用により、抗腫瘍効果を誘導する。

2. がんペプチドワクチン療法におけるエスケープ機序

そもそもがん細胞は、個体の有する自然および特異的免疫機構の監視機構を逃れて生育しているものとして捉えられる。この監視機構から逃れる多くの機序が確認されており、エスケープ機構としてその機序の解明と排除のための対応策についての研究が盛んに行なわれている。これらについては「腫瘍側の因子」と「T細胞側の因子」の双方での存在が知られている (表1)。担がん生体にこれらの現象のすべてが存在しているのではなく、その種類や程度はさまざまである。エスケープ機序に対する克服策は、がんワクチン療法の実施上、避けて通れぬ重要な課題対象である。個々のがんペプチドワクチン療

ヒストンアセチル化 (HAT)



ヒストン脱アセチル化 (HDAC)




図3 ヒストンアセチル化と脱アセチル化と遺伝子転写機構

表2 抗原提示分子の発現低下と発現回復を目的とした薬剤（文献7、表2の一部を紹介）

| 発現抑制遺伝子 | 研究対象がん腫 | 発現回復薬剤 | |
|------------------------------|----------|----------|---------|
| | | DNMT阻害剤 | HDAC阻害剤 |
| I. MHC class I | | | |
| | 神経芽細胞腫 | | TSA |
| | 前立腺がん | | TSA |
| | 巨核球性白血病 | | SB |
| | メラノーマ | 5-AZA・DC | |
| II. MHC class II | | | |
| | 神経芽細胞腫 | | TSA |
| | HeLa細胞 | | TSA |
| | 骨髄単球性白血病 | SB | |
| | B細胞リンパ腫 | | TSA |
| III. β 2-microglobulin | | | |
| | 前立腺がん | | TSA |
| IV. CIITA | | | |
| | 扁平上皮がん | | TSA |

法を実施する中で、in vivo, in vitroでのエスケープ機構の詳細な分析が、治療成績向上のための重要な基礎知見となりうるであろう。

近年、がん細胞クロマチンにおいて、過剰なDNAメチル化¹¹⁾あるいはヒストン脱アセチル化¹²⁾によって、ヒストンのN末端が陽性荷電となり陰性荷電のDNAと結合し転写が抑えられることが知られている。Methyl-CpG-binding protein (MBP)はヒストンメチル化酵素と結合し、N末端はメチル化し、その部分を認識するヘテロクロスチン蛋白 (HPI) が結合し、HPI同士が重合することによりその領域が凝縮される。増殖抑制遺伝子やアポトーシス誘導遺伝




図4 想定されるHDAC阻害剤の抗腫瘍効果

子の発現のための転写は抑制され（図3）、がんのエスケープ機構の重要なひとつとして幅広く関与していることが明らかとなっている^{13,14)}。

3. エピジェネティクス制御による免疫逃避機構の解除は可能か

前項で述べたようなエピジェネティクス免疫逃避機構が証明された結果、がん抗原遺伝子の増幅やHLAクラスI発現機構の修飾化、すなわちがん細胞におけるDNAメチル化現象あるいはヒストン脱アセチル化現象の阻害、そして細胞性免疫のCTL賦活化、などが治療法のひとつとして想定される。

HLAクラスIにおけるエスケープ機構に焦点を当てると、DNAメチル化酵素阻害剤¹⁵⁾、ヒストン脱アセチル化酵素阻害剤¹⁶⁾の有用性が想定される。すでに今日までにDNA methyltransferase (DMNT)阻害剤として5-aza-2'-deoxycytidine (5-AZA/DC)、histone deacetylase inhibitor (HDAC)阻害剤としてvalproic acid (VPA)、trichostatin A (TSA)、sodium

表3 進行・再発大腸癌に対するサバイビン2Bペプチド単剤による第一相臨床試験結果

| 症例 | 性/年 | stage | 投与量 | 投与回数 | 副作用 | 腫瘍マーカー | 画像評価 | DTH |
|----|------|-------|--------|------|-------|----------|------|-----|
| 1 | M/63 | IIIb | 0.1mg | 10 | 貧血 | 低下 | PR | - |
| 2 | M/53 | II | 0.1mg | 10 | 無 | 増加 | PD | - |
| 3 | M/42 | IV | 0.1mg | 17 | 無 | 増加（一時低下） | SD | - |
| 4 | F/54 | IIIb | 0.1mg | 2 | | | | |
| 5 | M/65 | I | 0.1mg | 14 | 無 | 増加（一時低下） | PD | - |
| 6 | F/64 | IV | 0.1mg | 6 | 全身倦怠感 | 増加（一時低下） | PD | + |
| 7 | F/48 | IV | 1.0mg | 7 | 無 | 低下 | PD | - |
| 8 | F/62 | II | 1.0mg | 13 | 無 | 増加 | PD | - |
| 9 | M/64 | IIIb | 1.0mg | 18 | 無 | 増加（一時低下） | PD | - |
| 10 | M/52 | IIIb | 1.0mg | 6 | 無 | 増加 | PD | + |
| 11 | M/58 | IV | 1.0mg | 14 | 無 | 増加 | SD | + |
| 12 | F/58 | II | 10.0mg | 12 | 発熱 | 増加 | PD | - |
| 13 | F/62 | II | 10.0mg | 6 | 無 | 増加 | PD | + |
| 14 | M/72 | IV | 10.0mg | 10 | 無 | 増加 | PD | + |
| 15 | M/71 | IV | 10.0mg | 4 | | | | |
| 16 | M/67 | IV | 10.0mg | 7 | 無 | 増加 | PD | - |
| 17 | F/59 | IV | 10.0mg | 9 | 無 | 増加 | SD | + |

butyrate(SB)は、すでに適応疾患を異にして市販されている。他に標的分子の特徴と、その特異的選択性を目指した阻害作用を示す薬剤開発研究も行われており、それらの臨床応用に期待が寄せられる¹⁷⁾。これまでに明らかにされた抗原提示関連分子の発現抑制遺伝子と発現回復薬剤を表2に要約した。これら薬剤の作用は図4に示したような抗腫瘍効果が期待される。

4. 第I相臨床治験成績

(1) 進行・再発大腸がんにおける臨床試験結果¹⁸⁾

(a) ペプチド単剤投与

17症例が臨床試験に登録され(表3)、ワクチン投与を開始したが、2症例(症例4、症例15)では本治験を途中で中止した。症例4は脳転移の増悪にてステロイド治療のため本治験を中止、症例15は肺転移の増悪にて治験終了となった。いずれも病状増悪による本治験中止であり、ワクチンの副作用による理由ではなかった。


有害事象は、貧血、全身倦怠感、発熱であったが、いずれもgrade2以下であり、このペプチドの安全性は評価しうると考えられた。

臨床効果としては、2例に腫瘍マーカーの低下を認めた。そのうち、臨床試験期間内に一時的にでも腫瘍マーカーが低下した症例は6例(症例1、3、5、6、7、9)あった。CTによる画像的評価では、3例にSD(stable disease)を認めた。また、直腸がんの吻合部再発である症例1においては、ペプチドワクチン投与開始前のCTと比較し、4回目のワクチン投与後のCTでは32%の腫瘍縮小を認めPR(partial response)と判定した。また、腫瘍縮小に伴って腫瘍マーカーも低下した(図5)。


6回のワクチン投与による臨床試験期間終了後は、腫瘍からの出血も消失し、全身状態もきわめて良好に改善されたため、その後、ワクチン投与を中断していた。すると、腫瘍マーカーは再上昇し始めた。そこで、再度ワクチン投与を再開すると、再び腫瘍マーカーは減少し始めた。このことから、ワクチ

a. CTにおける腫瘍径の変化
投与後に縮小化を生じている。

ワクチン投与前



ワクチン4回目投与後



b. CEA値の推移
再投与で高値化抑制がみられる。




図5 ワクチン投与経過時の検査結果

表4 再発進行性乳癌に対するSurvivin-2B単独投与の効果

| 患者 | ペプチド 投与量 | 有害事象 | 腫瘍マーカー値推移 | | CT上の 効果 | DTH skin test | Tetramer 染色 | ELISPOT assay | |
|----|-------------|------|-----------|-------|------------|------------------|----------------|------------------|-----|
| | | | マーカー | 投与前 | | | | | |
| 1 | 0.1 | (-) | ICTP** | 7.2 | 5.5 | PD | (+) | (-) | (-) |
| 2 | 0.1 | (-) | CEA** | 6.1 | 14.9 | PD | (-) | (-) | (-) |
| 3 | 0.1 | (-) | CA15-3*** | 323.7 | 412.1 | SD | (-) | (-) | (-) |
| 4 | 0.1 | (-) | CEA | 10.3 | 28.6 | PD | (-) | (-) | (-) |
| 5 | 0.1 | (-) | ICTP | 7.8 | 10.5 | SD | (+) | (-) | (-) |
| 6 | 1.0 | (-) | CA15-3 | 53.4 | 179.8 | PD | (-) | (-) | (-) |
| 7 | 1.0 | (-) | CEA | 72.5 | 15.2 | PD | (-) | (+) | (+) |
| 8 | 1.0 | (-) | WNR | | | | (-) | (-) | (-) |
| 9 | 1.0 | (-) | CEA | 22.5 | 45.2 | PD | (-) | (+) | (-) |
| 10 | 1.0 | (-) | CEA | 47.4 | 81.3 | PD | (-) | (+) | (-) |

*ワクチン投与後4週経過時測定、 **単位: ng/ml、 ***単位: U/ml

ン投与による抗腫瘍効果が実証されたと考えられる。

(b) アジュバント併用投与

IFAを併用投与するとほぼ全例に投与部位に硬結を認めた。IFAとIFN- α を併用すると、硬結以外に発熱を2症例に認めた。しかしながら、IFA併用、IFAとIFN- α 併用、いずれにおいてもgrade3以上の重篤な副作用を認めず、アジュバント併用サバイビン2Bペプチド投与においても安全性は評価された。

臨床効果としては、ペプチドワクチンにIFAを併用しても5例中1例(20%)にSDを認めたのみで、他症例ではすべてPR (progressive disease)であった。しかし、IFAにIFN- α を併用したところ5例中3例(60%)にSDを認め、IFN- α の有用なアジュバント効果を示したと考えられた。このことより、よりの確かなアジュバント設定がペプチドワクチン療法には重要であると考えられた。

(2) 進行・再発乳がんに対するペプチド単剤投与による臨床試験¹⁹⁾

進行・再発乳がんに対するペプチド単剤投与による臨床試験(表4)では、ペプチド投与量を2段階(0.1, 1.0mg)に設定し、それぞれ5例ずつに投与した。有害事象はいずれの症例にも認めなかった。

臨床効果においては、初回ペプチド投与前と4回目のペプチド投与後の腫瘍マーカー値を比較したところ2症例以外で上昇した。CT画像においては2症例にSDを認めたが、他症例ではPDであった。

免疫学的反応では、3症例でペプチド特異的CTLの頻度が増大、またそのうちの1症例ではELISPOT assayにてペプチド投与後にスポット数の増加を認めた。

次に、進行・再発乳がんに対するペプチドおよびIFA併用投与による臨床試験を試みた。本臨床試験では、ペプチド投与量を1.0mgに設定し、IFAとエマルジョン化し4症例に投与した。有害事象は2症例に投与部位の皮膚の硬結、1症例に全身倦怠感、1症例に全身倦怠感と発熱を認めた。しかしいずれも軽度で、ペプチドにIFAを併用しても安全性は確認された。

臨床反応としては、4症例いずれでも腫瘍マーカーは高値化し、CT評価においてもPDであった。しかし、免疫学的反応においてはすべての症例でペプチド特異的CTLの上昇を認め、そのうち1症例においてはELISPOT assayにおいてもスポット数の増大を認めた。

5. 臨床試験からの知見と新しい課題解決そして今後の展望

上述の臨床試験結果より、サバイビン2Bペプチドの安全性においては単剤投与、アジュバント併用投与のいずれにおいても問題はないと評価された。

サバイビン2Bペプチドによる抗腫瘍効果に関しては、乳がんでの結果よりペプチド単剤投与においては10症例中3症例(30%)にペプチド特異的CTL

の増加を認めたが、IFAを併用すると4症例すべての症例(100%)においてペプチド特異的CTLの増加を認めた。しかし4症例すべてでPDで、ペプチド投与によりペプチド特異的CTL誘導が可能であったが、腫瘍縮小を導くには至らなかった。

本稿においては提示していないが、ペプチドとIFAおよびIFN- α 併用の臨床試験では、再発腫瘍がんにおいて臨床試験開始後、腫瘍マーカーが正常域へ低下し、画像上もcancer freeな状態を長期にわたり維持している症例を経験しており、的確なアジュバントを併用することにより、満足すべき抗腫瘍臨床効果誘導が可能と思われた。

上記のように乳癌症例においては、ペプチド特異的CTL誘導が可能であったにもかかわらず、それが臨床効果に至らなかった原因の一つには、がん細胞の免疫エスケープ現象の関与が考えられた。特異的CTLはがん細胞表面に発現する抗原提示分子HLAクラスI分子発現を免疫染色にて解析したところ、ワクチン療法にてPRを認めた症例および腫瘍マーカーが正常値に低下した症例の多くで、がん原発巣でのHLAクラスI分子が強発現していた²⁰⁾。

このことより、ペプチドワクチン療法において高い抗腫瘍効果を誘導するには、がん病巣部でのHLAクラスI分子発現が低下していないか否かを確認する必要がある。つまり、よりの確かな症例の絞り込みが必要であると考えられた。また、がん細胞上のHLAクラスI分子発現低下には、エピジェネティック機構の介在が確認されている。われわれの研究グループの成果により、このような変化がヒストン脱アセチル阻害剤によって回復することもin vitroにおいて実証されている。

したがって、HLAクラスI分子がすでに発現低下、消失している症例においても、HLAクラスI分子の発現レベルを回復させることができるならば、多くの症例において高い抗腫瘍効果を誘導でき得ると考えられ、発現低下したHLAクラスI分子の発現回復方法の確立に向けて、早々に臨床試験が開始される予定である。

おわりに

2003年4月より、サバイビン2Bペプチドによる第I相臨床試験を展開してきている。確かに単剤投与でも有用例がみられた他、すべてのがん腫に臨床応用可能な基礎的知見が得られている。一方、十分な抗腫瘍効果誘導には至っていない症例に対する臨床解決を示し得ていないことも事実である。現在までに画期的な抗腫瘍効果を認めた症例が経験されており、今後のアジュバントの選択やエピジェネティクス修飾の確など、的確な薬剤投与設定が臨床適用に対し定まりつつある。

これまでの臨床試験において満足すべき抗腫瘍効果を誘導できない最大原因の一つに、各種の治療を

踏み終えた進行・再発状態を対象にしていることが考えられる。したがって、今後は再発治療のfirst-lineとして化学療法との併用、あるいは術後補助療法としてのペプチドワクチン療法、臨床試験が予定されるべきである。今後、ペプチドワクチン療法が、手術、化学療法あるいは放射線療法とともに、がん集学的治療の一つとして確立されることが期待されている。

参考文献

1. Queirolo, P., Ponte, M., Gipponi, M., et al: Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. *Melanoma Istituto Scientifico Tumori Group. Ann Surg Oncol* 6 :272-278, 1999.
2. Figlin, R. A., Thompson, J. A., Bukowski, R. M. et al: Multicenter, randomized, phase III trial of CD8 (+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. *J Clin Oncol* 17:2521-2529, 1999.
3. Rosenberg SA, Yang JC, Schwartzentruber DJ et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat Med* 4 :321-327, 1998.
4. 鶴間哲弘:がんペプチドワクチン療法の最前線. *ファルマシア* 41:749-753, 2005.
5. Kawakami Y, Rosenberg SA: T-cell recognition of self peptides as tumor rejection antigens. *Immunol Res* 15:179-190, 1996.
6. 池田英之、佐藤昇志: T細胞の認識する癌抗原同定と癌免疫療法. *札幌医誌* 71:47-51, 2002.
7. 中津川宗秀、鳥越俊彦: エピジェネティクスにより制御される腫瘍の免疫逃避機構. *Annual Review 免疫* 2008;203-209, 2008.
8. Nestle, F. O., Banchereau, J. and Hart, D.: Dendritic cells: On the move from bench to bedside. *Nat Med* 7 :761-765, 2001.
9. 平田公一、鶴間哲弘、鳥越俊彦、佐藤昇志: 癌ワクチン療法の概念と現状. *Surgery Frontier* 13:5-7, 2006.
10. Chang, A. E., Aruga, A., Cameron, M. J., et al: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated

- with anti-CD3 and interleukin-2. *J Clin Oncol* 15:796-807, 1997.
11. Kanasaki T, Ikeda H, Takamura Y, et al: Histone deacetylating, but not hypermethylating, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. *J Immunol* 170:4980-4985, 2003.
12. Ryan QC, Headlee D, Acharya M, et al: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. *J Clin Oncol* 23:3912-22, 2005.
13. Eramo A, Pallini R, Lotti F, et al. Inhibition on DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. *Cancer Res* 65:11469-11477, 2005.
14. Insinga A, Monestiroli S, Ronzoni S, et al: Inhibitors of histone deacetylases induce tumor elective apoptosis through activation of the death receptor pathway. *Nat Med* 11:71-76, 2005.
15. Srrano A, Tanzerella S, Lionello I, et al. Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. *Int J Cancer* 94:243-51, 2001.
16. Kanaseki T, Ikeda H, Takamura Y, et al: Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. *J Immunol* 170:4980-5, 2003.
17. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. *Nat Rev Drug Discov* 5 :37-50, 2006.
18. 岩山祐司、古畑智久、大村東生、他: 癌ワクチン療法. *外科治療* 96:378-382, 2007.
19. 鶴間哲弘、亀嶋秀和、岩山祐司、他: サバイビン2Bペプチドワクチン療法. 一第I相臨床試験からの知見. *Biotherapy* 23:178-184, 2009.
20. Kiramura H, Torigoe A, Asanuma H, et al: Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. *J Urol* 178:692-696, 2007.